- Home
- IPA vs SYBX Comparison
IPA vs SYBX Comparison
Compare IPA & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- SYBX
- Stock Information
- Founded
- IPA 1983
- SYBX N/A
- Country
- IPA Canada
- SYBX United States
- Employees
- IPA N/A
- SYBX N/A
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- IPA Health Care
- SYBX Health Care
- Exchange
- IPA Nasdaq
- SYBX Nasdaq
- Market Cap
- IPA 15.3M
- SYBX 16.5M
- IPO Year
- IPA 2017
- SYBX N/A
- Fundamental
- Price
- IPA $0.53
- SYBX $1.46
- Analyst Decision
- IPA Strong Buy
- SYBX Hold
- Analyst Count
- IPA 2
- SYBX 3
- Target Price
- IPA $5.00
- SYBX $1.00
- AVG Volume (30 Days)
- IPA 422.7K
- SYBX 25.8K
- Earning Date
- IPA 03-13-2025
- SYBX 11-12-2024
- Dividend Yield
- IPA N/A
- SYBX N/A
- EPS Growth
- IPA N/A
- SYBX N/A
- EPS
- IPA N/A
- SYBX N/A
- Revenue
- IPA $17,272,336.00
- SYBX $2,777,000.00
- Revenue This Year
- IPA $1.88
- SYBX N/A
- Revenue Next Year
- IPA $9.90
- SYBX N/A
- P/E Ratio
- IPA N/A
- SYBX N/A
- Revenue Growth
- IPA 6.36
- SYBX 292.23
- 52 Week Low
- IPA $0.33
- SYBX $1.22
- 52 Week High
- IPA $2.60
- SYBX $3.73
- Technical
- Relative Strength Index (RSI)
- IPA 58.77
- SYBX 53.64
- Support Level
- IPA $0.43
- SYBX $1.36
- Resistance Level
- IPA $0.59
- SYBX $1.47
- Average True Range (ATR)
- IPA 0.07
- SYBX 0.08
- MACD
- IPA 0.01
- SYBX 0.00
- Stochastic Oscillator
- IPA 71.48
- SYBX 62.50
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.